Effort-Related Motivational Effects of the VMAT-2 Inhibitor Tetrabenazine: Implications for Animal Models of the Motivational Symptoms of Depression
Nunes E, Randall P, Hart E, Freeland C, Yohn S, Baqi Y, Müller C, López-Cruz L, Correa M, Salamone J. Effort-Related Motivational Effects of the VMAT-2 Inhibitor Tetrabenazine: Implications for Animal Models of the Motivational Symptoms of Depression. Journal Of Neuroscience 2013, 33: 19120-19130. PMID: 24305809, PMCID: PMC3850037, DOI: 10.1523/jneurosci.2730-13.2013.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine A2 Receptor AntagonistsAdrenergic Uptake InhibitorsAnimalsAntidepressive Agents, Second-GenerationBehavior, AnimalBupropionConditioning, OperantDepressionDisease Models, AnimalDopamineDopamine and cAMP-Regulated Phosphoprotein 32EnkephalinsFeeding BehaviorImmunohistochemistryMaleMicrodialysisMotivationNucleus AccumbensProto-Oncogene Proteins c-fosRatsRats, Sprague-DawleySubstance PTetrabenazineVesicular Monoamine Transport ProteinsXanthinesConceptsMotivational symptomsAnimal modelsEffort-related choice behaviorAdenosine A2A antagonist MSX-3Vesicular monoamine transport (VMAT-2) inhibitor tetrabenazineEffort-related motivational effectsEffort-related motivational symptomsAccumbens medium spiny neuronsVMAT-2 inhibitor tetrabenazineD2 DA receptorsDepression-like effectsDose-related decreaseMedium spiny neuronsEffects of tetrabenazineInhibitor tetrabenazineEffort-related choiceEffort-related effectsDA receptorsAntidepressant bupropionChow intakeMSX-3Spiny neuronsMajor depressionExtracellular dopamineFood intakeThe vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor
Podurgiel S, Nunes E, Yohn S, Barber J, Thompson A, Milligan M, Lee C, López-Cruz L, Pardo M, Valverde O, Lendent C, Baqi Y, Müller C, Correa M, Salamone J. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor. Neuroscience 2013, 250: 507-519. PMID: 23867769, DOI: 10.1016/j.neuroscience.2013.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAnimalsCatalepsyData Interpretation, StatisticalDisease Models, AnimalDose-Response Relationship, DrugJawMaleMiceMice, KnockoutMotor ActivityMovementParkinsonian DisordersProto-Oncogene Proteins c-fosRatsRats, Sprague-DawleyReceptor, Adenosine A2ATetrabenazineTremorVesicular Monoamine Transport ProteinsXanthinesConceptsTremulous jaw movementsVentrolateral neostriatumC-fos expressionMSX-3Receptor transmissionAdenosine A2A antagonist MSX-3A2A receptor knockout miceParkinsonian tremorC-Fos-positive cellsAbility of tetrabenazineParkinsonian side effectsVesicular monoamine storageJaw movementsReceptor knockout miceAdenosine A2A receptorsOral tremorWild-type controlsPharmacological antagonismStriatal dopamineLocomotor suppressionMotor effectsCD1 miceRodent modelsKnockout miceSide effects